Biognosys AG

Based in Switzerland, Biognosys AG specializes in proteomics solutions that enhance biomarker discovery and drug development in the pharmaceutical and biotech sectors. Biognosys AG, founded in 2008 and headquartered in Dietikon, Switzerland, focuses on advanced proteomics solutions. The company has undergone a strategic shift by being acquired by Bruker Corporation, enhancing its capabilities in pharmacoproteomics. The firm has successfully closed a total of 7 deals, with the most recent being a TRADE SALE on January 3, 2023, where it raised CHF 72.

5 million to expand its operations. CEO Oliver Rinner leads the company, which is poised for growth following this significant investment. Biognosys specializes in next-generation proteomics solutions aimed at advancing biomarker discovery and drug development. Their core product offerings include a suite of software solutions such as Spectronaut®, which supports data-independent acquisition (DIA) proteomics; SpectroDive™ for targeted proteomics; SpectroMine™ designed for data-dependent acquisition (DDA) proteomics; and the QC tool QuiC™.

These software solutions enable researchers across the pharmaceutical and biotech sectors to obtain unbiased biological insights from various samples, including tissue and biofluids. Additionally, Biognosys provides peptide kits and reagents, such as the PQ500™ Reference Peptides for plasma proteomics quantification and iRT kits for quality control, facilitating in-house proteomics research. Their products cater primarily to clients in North America, Europe, and parts of Asia, particularly targeting pharmaceutical companies and academic institutions engaged in clinical research and development. Biognosys generates revenue through a combination of contract research services, software licensing, and the sale of peptide kits and reagents.

The company typically engages in B2B transactions with pharmaceutical and biotech firms, offering both subscription-based access to their software products and one-time purchase options for their reagents and kits. These partnerships may include long-term agreements for the use of their patented platforms, particularly in high-throughput proteomics research, allowing clients to conduct extensive studies on drug targets and biomarkers. Each software solution is offered under specific licensing terms, while reagents are sold individually or as part of bundled kits, enhancing accessibility for researchers. The firm’s flagship product, Spectronaut®, is a key driver in this revenue model, catering to a wide client base that seeks advanced capabilities in proteomics analysis.

Following the TRADE SALE to Bruker Corporation in January 2023, which resulted in CHF 72. 5 million in funding, Biognosys plans to leverage this capital to expand into the US market and support the development of pharmacoproteomics clinical trials. The acquisition will enable the company to accelerate the launch of new products designed specifically for market needs and enhance its operational capabilities in providing proteomics solutions.